CoChat
Sign Up
Cited by 20Renin-Angiotensin System StudiesEicosanoids and Hypertension PharmacologyRenal and Vascular Pathologies

Pathobiological Interactions of Local Bone Marrow Renin-Angiotensin System and Central Nervous System in Systemic Arterial Hypertension

Open access
Ciftciler, Rafiye, Haznedaroglu, Ibrahim Celalettin·2020·Frontiers in Endocrinology
DOI 10.3389/fendo.2020.00425PMC PMC7438890
Open this paper in CoChat — free accountOpen PDF

Abstract

Circulating renin-angiotensin system (RAS) and local paracrin-autocrin-intracrin tissue-based RAS participate in numerous pathobiological events. Pro-inflammatory, pro-fibrotic, and pro-thrombotic consequences associated with local RAS activation have been detected at cellular and molecular level. Regenerative progenitor cell therapy in response to RAS modulating pharmacotherapy has emerged as an adjunct in the context of endothelial cell injury and regeneration to improve regeneration of the vascular endothelium. Local hematopoietic bone marrow (BM) RAS symbolizes the place of cross-interaction between vascular biology and cellular events from embryogenesis to definitive hematopoiesis underlying vascular atherosclerosis. The BM microenvironment also contains Mas receptors, which control the proliferative role of Ang 1-7 on hematopoietic stem cells. Ang 1-7 is produced from Ang-II or Ang-I with the help of ACE2. Various tissues and organs also have an effect on the RAS system. The leukocytes contain and synthesize immunoreactive angiotensinogen species capable of producing angiotensin in the basal state or after incubation with renin. The significance of RAS employment in atherosclerosis and hypertension was indicated by novel bidirectional Central Nervous System (CNS) RAS-BM RAS communications. Myeloid cells generated within the context of hematopoietic BM RAS are considered as the initiators and decision shapers in atherosclerosis. Macrophages in the atherosclerotic lesions contain angiotensin peptides by which RAS blockers inhibit monocyte activation and adherence. Furthermore, vascular biology in relation to inflammation and neoplasia is also affected by local tissue RAS. The purpose of this article is to outline interactions of circulating and local angiotensin systems, especially local bone marrow RAS, in the vascular pathobiological microenvironment of CNS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2020.00425

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 90

  1. [1]Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Ann Rev Pharmacol Toxicol. (2010) 50: 439– 65. 10.1146/annurev.pharmtox.010909.105610 20055710 · DOI
  2. [2]Nehme A Zouein FA Deris Zayeri Z Zibara K. An update on the tissue renin angiotensin system and its role in physiology and pathology. J Cardiovasc Develop Dis. (2019) 6: 14. 10.3390/jcdd6020014 30934934 PMC6617132 · DOI
  3. [3]Haznedaroglu I Tuncer S Gürsoy MJ. A local renin-angiotensin system in the bone marrow. Med Hypotheses. (1996) 46: 507– 10. 10.1016/S0306-9877(96)90122-X 8803932 · DOI
  4. [5]Haznedaroglu IC Malkan UY. Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies. Eur Rev Med Pharmacol. (2016) 20: 4089– 111. 27775788
  5. [6]Beyazit Y Purnak T Guven GS Haznedaroglu IC. Local bone marrow renin-angiotensin system and atherosclerosis. Caridiol Res Pract. (2011). 2011: 714515. 10.4061/2011/714515 21234405 PMC3014698 · DOI
  6. [7]Zubcevic J Santisteban MM Pitts T Baekey DM Perez PD Bolser DC. Functional neural–bone marrow pathways: implications in hypertension and cardiovascular disease. Hypertension. (2014) 63: e129– 39. 10.1161/HYPERTENSIONAHA.114.02440 24688127 PMC4295780 · DOI
  7. [8]Jun JY Zubcevic J Qi Y Afzal A Carvajal JM Thinschmidt JS. Brain-mediated dysregulation of the bone marrow activity in angiotensin II–induced hypertension. Hypertension. (2012) 60: 1316– 23. 10.1161/HYPERTENSIONAHA.112.199547 23045460 PMC3482108 · DOI
  8. [9]Santisteban MM Zubcevic J Baekey DM Raizada MK. Dysfunctional brain-bone marrow communication: a paradigm shift in the pathophysiology of hypertension. Curr Hypertension Rep. (2013) 15: 377– 89. 10.1007/s11906-013-0361-4 23715920 PMC3714364 · DOI
  9. [10]Strawn WB Richmond RS Ann Tallant E Gallagher PE Ferrario CM. Renin–angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol. (2004) 126: 120– 6. 10.1111/j.1365-2141.2004.04998.x 15198742 · DOI
  10. [11]Haznedaroglu IC Beyazit YJJotR-A-AS. Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. J Renin Angiotensin Syst. (2010) 11: 205– 13. 10.1177/1470320310379876 20807797 · DOI
  11. [12]Haznedaroglu IC Oztürk MA. Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int J Biochem Cell Biol. (2003) 35: 867– 80. 10.1016/S1357-2725(02)00278-9 12676173 · DOI
  12. [13]Hubert C Savary K Gasc J-M Corvol P. The hematopoietic system: a new niche for the renin–angiotensin system. Nat Clin Cardiovasc Med. (2006) 3: 80– 5. 10.1038/ncpcardio0449 16446776 · DOI
  13. [14]Lin C Datta V Okwan-Duodu D Chen X Fuchs S Alsabeh R. Angiotensin-converting enzyme is required for normal myelopoiesis. FASEB J. (2011) 25: 1145– 55. 10.1096/fj.10-169433 21148418 PMC3058713 · DOI
  14. [15]Kato H Ishida J Imagawa S Saito T Suzuki N Matsuoka T. Enhanced erythropoiesis mediated by activation of the renin-angiotensin system via angiotensin II type 1a receptor. FASEB J. (2005) 19: 2023– 5. 10.1096/fj.05-3820fje 16223784 · DOI
  15. [16]Kwiatkowski BA Richard RE Angiotensin II receptor-associated protein (AGTRAP) synergizes with Mpl signaling to promote survival and to increase proliferation rate of hematopoietic cells. Blood. (2009) 114: 3606 10.1182/blood.V114.22.3606.3606 · DOI
  16. [17]Durik M Sevá Pessôa B Roks AJJCS. The renin–angiotensin system, bone marrow and progenitor cells. Clin Sci. (2012) 123: 205– 23. 10.1042/CS20110660 22548406 · DOI
  17. [18]Heringer-Walther S Eckert K Schumacher S-M Uharek L Wulf-Goldenberg A Gembardt F. Angiotensin-(1–7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica. (2009) 94: 857– 60. 10.3324/haematol.2008.000034 19377080 PMC2688578 · DOI
  18. [19]Haznedaroglu IC Beyazit Y. Local bone marrow renin–angiotensin system in primitive, definitive and neoplastic haematopoiesis. Clin Sci. (2013) 124: 307– 23. 10.1042/CS20120300 23157407 · DOI
  19. [20]Park TS Zambidis ETJH. A role for the renin-angiotensin system in hematopoiesis. Haematologica. (2009) 94: 745. 10.3324/haematol.2009.006965 19483149 PMC2688560 · DOI
  20. [21]Comte L Lorgeot V Bignon J Volkov L Dupuis F Wdzieczak-Bakala J. In vivo modifications of AcSDKP metabolism and haematopoiesis in mice treated with 5-fluorouracil and Goralatide. Eur J Clin Invest. (1998) 28: 856– 63. 10.1046/j.1365-2362.1998.00356.x 9793000 · DOI
  21. [22]Arici M Büyükaşik YJM. A unifying hypothesis for the renin–angiotensin system and hematopoiesis: sticking the pieces together with the JAK-STAT pathway. Med Hypotheses. (2000) 54: 80– 3. 10.1054/mehy.1998.0830 10790731 · DOI
  22. [23]Öztürk MA Güven GS Haznedaroglu IC. How hematopoietic stem cells know and act in cardiac microenvironment for stem cell plasticity? Impact of local renin–angiotensin systems. Med Hypotheses. (2004) 63: 866– 74. 10.1016/j.mehy.2004.04.011 15488662 · DOI
  23. [24]Rodgers K Xiong S. Effect of angiotensin II and angiotensin (1–7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother Pharmacol. (2003) 51: 97– 106. 10.1007/s00280-002-0509-4 12647010 · DOI
  24. [25]Rodgers KE Oliver J. Phase I/II dose escalation study of angiotensin 1-7 [A (1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol. (2006) 57: 559– 68. 10.1007/s00280-005-0078-4 16096787 · DOI · Paper page
  25. [26]Ferrario CM Angiotensin I, angiotensin II and their biologically active peptides. J Hypertension. (2002) 20: 805– 7. 10.1097/00004872-200205000-00004 12011630 · DOI
  26. [27]Jarajapu YP. Targeting ACE2/angiotensin-(1-7)/mas receptor axis in the vascular progenitor cells for cardiovascular diseases. Mol Pharmacol. (2020) 98: mol.119.117580. 10.1124/mol.119.117580 32321734 PMC7725063 · DOI
  27. [28]Gomez RA Norling LL Wilfong N Isakson P Lynch KR Hock R. Leukocytes synthesize angiotensinogen. Hypertension. (1993) 21: 470– 5. 10.1161/01.HYP.21.4.470 7681424 · DOI
  28. [29]Dezsö B Jacobsen J Poulsen K. Evidence for the presence of angiotensins in normal, unstimulated alveolar macrophages and monocytes. J Hypertension. (1989) 7: 5– 11. 10.1097/00004872-198901000-00002 2708812 · DOI
  29. [30]Ehlers MR Riordan JF. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry. (1989) 28: 5311– 8. 10.1021/bi00439a001 2476171 · DOI
  30. [31]Jokubaitis VJ Sinka L Driessen R Whitty G Haylock DN Bertoncello I. Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood. (2008) 111: 4055– 63. 10.1182/blood-2007-05-091710 17993616 · DOI
  31. [32]Tavian M Biasch K Sinka L Vallet J Péault B. Embryonic origin of human hematopoiesis. Int J Dev Boil. (2010) 54: 1061– 5. 10.1387/ijdb.103097mt 20711983 · DOI
  32. [33]Sinka L Biasch K Khazaal I Péault B Tavian MJB. Angiotensin-converting enzyme (CD143) specifies emerging lympho-hematopoietic progenitors in the human embryo. Blood. (2012) 119: 3712– 23. 10.1182/blood-2010-11-314781 22282502 · DOI
  33. [34]Aksu S Beyazit Y Haznedaroglu IC Canpinar H Kekilli M Uner A. Over-expression of angiotensin-converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML. Leuk Lymphoma. (2006) 47: 891– 6. 10.1080/10428190500399250 16753875 · DOI
  34. [35]Beyazit Y Aksu S Haznedaroglu IC Kekilli M Misirlioglu M Tuncer S. Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. J Natl Med Assoc. (2007) 99: 57. 17304969 PMC2569610
  35. [36]Wulf GG Jahns-Streubel G Nobiling R Strutz F Hemmerlein B Hiddemann W. Renin in acute myeloid leukaemia blasts. Br J Haematol. (1998) 100: 335– 7. 10.1046/j.1365-2141.1998.00565.x 9488623 · DOI
  36. [37]Yamashita T Ahmad S Wright KN Roberts DJ VonCannon JL Wang H. Noncanonical mechanisms for direct bone marrow generating Ang II (angiotensin II) predominate in CD68 positive myeloid lineage cells. Hypertension. (2020) 75: 500– 9. 10.1161/HYPERTENSIONAHA.119.13754 31813348 PMC6949383 · DOI
  37. [38]Shen XZ Bernstein KE. The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis. Cell Cycle. (2011) 10: 1363– 9. 10.4161/cc.10.9.15444 21441775 PMC3117040 · DOI
  38. [39]Gallagher PE Tallant EA Ferrario CM Angiotensin converting enzyme 2: a critical regulator of the renin-angiotensin system. Circ Res. (2006) 126: 129– 42. 10.1007/0-387-27826-5_11 · DOI
  39. [40]Belyea BC Xu F Pentz ES Medrano S Li M Hu Y. Identification of renin progenitors in the mouse bone marrow that give rise to B-cell leukaemia. Nat Commun. (2014) 5: 1– 14. 10.1038/ncomms4273 24549417 PMC3929784 · DOI
  40. [41]Nehme A Cerutti C Dhaouadi N Gustin MP Courand P-Y Zibara K. Atlas of tissue renin-angiotensin-aldosterone system in human: a transcriptomic meta-analysis. Sci Rep. (2015) 5: 10035. 10.1038/srep10035 25992767 PMC4445654 · DOI
  41. [42]Tanaka K Sata M. Role of vascular progenitor cells in cardiovascular disease. Curr Pharm Design. (2009) 15: 2760– 8. 10.2174/138161209788923868 19689346 · DOI
  42. [43]de Souza-Neto FP Santuchi MC e Silva MdM Campagnole-Santos MJ da Silva RF. Angiotensin-(1–7) and alamandine on experimental models of hypertension and atherosclerosis. Curr Hypertens Rep. (2018) 20: 17. 10.1007/s11906-018-0798-6 29541937 · DOI
  43. [44]Mazzolai L Hayoz DJ. The renin-angiotensin system and atherosclerosis. Curr Hyperten Rep. (2006) 8: 47– 53. 10.1007/s11906-006-0040-9 16600159 · DOI
  44. [45]Durante A Peretto G Laricchia A Ancona F Spartera M Mangieri A. Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Curr Pharm Des. (2012) 18: 981– 1004. 10.2174/138161212799436467 22283771 · DOI
  45. [46]Husain K Hernandez W Ansari RA Ferder L. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem. (2015) 6: 209. 10.4331/wjbc.v6.i3.209 26322175 PMC4549761 · DOI
  46. [47]Fukuda D Sata M. Role of bone marrow renin–angiotensin system in the pathogenesis of atherosclerosis. Pharmacol Ther. (2008) 118: 268– 76. 10.1016/j.pharmthera.2008.02.007 18439685 · DOI
  47. [48]Rodgers KE Xiong S Steer R DiZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. (2000) 18: 287– 94. 10.1634/stemcells.18-4-287 10924095 · DOI
  48. [49]Daugherty A Rateri DL Lu H Inagami T Cassis LA. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation. (2004) 110: 3849– 57. 10.1161/01.CIR.0000150540.54220.C4 15596561 · DOI
  49. [50]Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. (1999) 340: 115– 26. 10.1056/NEJM199901143400207 9887164 · DOI · Paper page
  50. [51]Libby P Ridker PM Hansson GKJN. Progress and challenges in translating the biology of atherosclerosis. Nature. (2011). 473: 317– 25. 10.1038/nature10146 21593864 · DOI · Paper page
  51. [52]Flaherty ML Kissela B Khoury JC Alwell K Moomaw CJ Woo D. Carotid artery stenosis as a cause of stroke. Neuroepidemiology. (2013) 40: 36– 41. 10.1159/000341410 23075828 PMC3626492 · DOI
  52. [53]Banerjee C Chimowitz MI. Stroke caused by atherosclerosis of the major intracranial arteries. Circ Res. (2017) 120: 502– 13. 10.1161/CIRCRESAHA.116.308441 28154100 PMC5312775 · DOI
  53. [54]Arenillas JF. Intracranial atherosclerosis: current concepts. Stroke. (2011) 42(Suppl. 1): S20– 3. 10.1161/STROKEAHA.110.597278 21164126 · DOI
  54. [56]Liu Y Yu H Zhang Y Zhao Y. TLRs are important inflammatory factors in atherosclerosis and may be a therapeutic target. Med Hypotheses. (2008) 70: 314– 6. 10.1016/j.mehy.2007.05.030 17689203 · DOI
  55. [57]Hansson GK Libby P Tabas I. Inflammation and plaque vulnerability. J Intern Med. (2015) 278: 483– 93. 10.1111/joim.12406 26260307 PMC5082111 · DOI
  56. [59]Group FSoAPiS. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med. (1996) 334: 1216– 21. 10.1056/NEJM199605093341902 8606716 · DOI
  57. [60]Ohira T Shahar E Chambless LE Rosamond WD Mosley TH Folsom AR. Risk factors for ischemic stroke subtypes: the atherosclerosis risk in communities study. Stroke. (2006) 37: 2493– 8. 10.1161/01.STR.0000239694.19359.88 16931783 · DOI
  58. [61]Chambless LE Folsom AR Clegg LX Sharrett AR Shahar E Nieto FJ. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. (2000) 151: 478– 87. 10.1093/oxfordjournals.aje.a010233 10707916 · DOI
  59. [62]Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. (2010) 120: 287– 96. 10.1007/s00401-010-0718-6 20623294 PMC3001188 · DOI · Paper page
  60. [63]Saji N Toba K Sakurai TJP. Cerebral small vessel disease and arterial stiffness: tsunami effect in the brain. Pulse. (2015) 3: 182– 9. 10.1159/000443614 27195239 PMC4865071 · DOI
  61. [64]Yamazaki K Allen TD. Ultrastructural morphometric study of efferent nerve terminals on murine bone marrow stromal cells, and the recognition of a novel anatomical unit: The “neuro-reticular complex”. Am J Anatomy. (1990) 187: 261– 76. 10.1002/aja.1001870306 2321559 · DOI
  62. [65]Miyan J Broome C Whetton A. Neural regulation of bone marrow. Blood. (1998) 92: 2971– 3. 10.1182/blood.V92.8.2971b.splL2_2971_2972 9763586 · DOI
  63. [66]MacEneaney OJ DeSouza CA Weil BR Kushner EJ Van Guilder GP Mestek M. Prehypertension and endothelial progenitor cell function. J Hum Hypertension. (2011) 25: 57– 62. 10.1038/jhh.2010.31 20336149 PMC2895004 · DOI
  64. [67]Giannotti G Doerries C Mocharla PS Mueller MF Bahlmann FH Horvàth T. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension. (2010) 55: 1389– 97. 10.1161/HYPERTENSIONAHA.109.141614 20458006 · DOI
  65. [68]Yao EH Yu Y Fukuda N. Oxidative stress on progenitor and stem cells in cardiovascular diseases. Curr Pharmac Biotechnol. (2006) 7: 101– 8. 10.2174/138920106776597685 16724944 · DOI
  66. [69]Imanishi T Hano T Nishio I. Estrogen reduces endothelial progenitor cell senescence through augmentation of telomerase activity. J Hypertension. (2005) 23: 1699– 706. 10.1097/01.hjh.0000176788.12376.20 16093915 · DOI
  67. [70]Ganten D Speck G. The brain renin-angiotensin system: a model for the synthesis of peptides in the brain. Biochem Pharmacol. (1978) 27: 2379– 89. 10.1016/0006-2952(78)90348-9 365183 · DOI
  68. [71]Karamyan VT Speth RC. Enzymatic pathways of the brain renin-angiotensin system: unsolved problems and continuing challenges. Regul Pept. (2007) 143: 15– 27. 10.1016/j.regpep.2007.03.006 17493693 PMC7114358 · DOI
  69. [72]Santos R Brosnihan KB Chappell MC Pesquero J Chernicky CL Greene LJ. Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension. (1988) 11(2 Pt 2): I153. 10.1161/01.HYP.11.2_Pt_2.I153 2831145 · DOI
  70. [73]Block C Santos R Brosnihan K Ferrario CJP. Immunocytochemical localization of angiotensin-(1–7) in the rat forebrain. Peptides. (1988) 9: 1395– 401. 10.1016/0196-9781(88)90208-2 3247256 · DOI
  71. [74]Brosnihan KB Schiavone M Sprunger A Chappell MC Rizzo M Ferrario CMJH. In vivo release of angiotensin II from the rat hypothalamus. Hypertension. (1988) 11(2 Pt 2): I158. 10.1161/01.HYP.11.2_Pt_2.I158 3346050 · DOI
  72. [75]Zubcevic J Waki H Raizada MK Paton JFJH. Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. Hypertension. (2011) 57: 1026– 33. 10.1161/HYPERTENSIONAHA.111.169748 21536990 PMC3105900 · DOI
  73. [76]Bardgett ME Holbein WW Herrera-Rosales M Toney GM. Ang II–salt hypertension depends on neuronal activity in the hypothalamic paraventricular nucleus but not on local actions of tumor necrosis factor-α. Hypertenion. (2014) 63: 527– 34. 10.1161/HYPERTENSIONAHA.113.02429 24324037 PMC3945171 · DOI
  74. [77]Toney GM Pedrino GR Fink GD Osborn JW. Does enhanced respiratory–sympathetic coupling contribute to peripheral neural mechanisms of angiotensin II–salt hypertension? Exp Physiol. (2010) 95: 587– 94. 10.1113/expphysiol.2009.047399 20228120 PMC2978666 · DOI
  75. [78]Shan Z Zubcevic J Shi P Jun JY Dong Y Murça TM. Chronic knockdown of the nucleus of the solitary tract AT1 receptors increases blood inflammatory-endothelial progenitor cell ratio and exacerbates hypertension in the spontaneously hypertensive rat. Hypertension. (2013) 61: 1328– 33. 10.1161/HYPERTENSIONAHA.111.00156 23547238 PMC4128231 · DOI
  76. [80]Zubcevic J Jun JY Kim S Perez PD Afzal A Shan Z. Altered inflammatory response is associated with an impaired autonomic input to the bone marrow in the spontaneously hypertensive rat. Hypertension. (2014) 63: 542– 50. 10.1161/HYPERTENSIONAHA.113.02722 24366083 PMC3945212 · DOI · Paper page
  77. [81]Casanova-Acebes M Pitaval C Weiss LA Nombela-Arrieta C Chèvre R Noelia A. Rhythmic modulation of the hematopoietic niche through neutrophil clearance. Cell. (2013) 153: 1025– 35. 10.1016/j.cell.2013.04.040 23706740 PMC4128329 · DOI
  78. [82]Méndez-Ferrer S Lucas D Battista M Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. Nature. (2008) 452: 442– 7. 10.1038/nature06685 18256599 · DOI
  79. [83]Swirski FK Nahrendorf M Etzrodt M Wildgruber M Cortez-Retamozo V Panizzi P. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. (2009) 325: 612– 6. 10.1126/science.1175202 19644120 PMC2803111 · DOI · Paper page
  80. [84]Malhotra D Fletcher AL Turley SJ. Stromal and hematopoietic cells in secondary lymphoid organs: partners in immunity. Immunol Rev. (2013) 251: 160– 76. 10.1111/imr.12023 23278748 PMC3539229 · DOI · Paper page
  81. [85]Crowley SD Song Y-S Sprung G Griffiths R Sparks M Yan M. A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II–dependent hypertension. Hypertension. (2010) 55: 99– 108. 10.1161/HYPERTENSIONAHA.109.144964 19996062 PMC3676183 · DOI
  82. [86]Hristov M Zernecke A Bidzhekov K Liehn EA Shagdarsuren E Ludwig A. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res. (2007) 100: 590– 7. 10.1161/01.RES.0000259043.42571.68 17272812 · DOI
  83. [87]Zhu XY Urbieta-Caceres V Krier JD Textor SC Lerman A Lerman LO. Mesenchymal stem cells and endothelial progenitor cells decrease renal injury in experimental swine renal artery stenosis through different mechanisms. Stem Cells. (2013) 31: 117– 25. 10.1002/stem.1263 23097349 PMC3528811 · DOI
  84. [88]Feitelson J Kulenovic E Beck D Harris P Passmore J Malkani A. Endogenous norepinephrine regulates blood flow to the intact rat tibia. J Orthopaedic Res. (2002) 20: 391– 6. 10.1016/S0736-0266(01)00121-8 11924647 · DOI
  85. [89]Hollis M Wang DH. Transient receptor potential vanilloid in blood pressure regulation. Curr Opin Nephrol Hypertension. (2013) 22: 170– 6. 10.1097/MNH.0b013e32835c8d4c 23274405 · DOI
  86. [90]Wang Y Wang DH. Neural control of blood pressure: focusing on capsaicin-sensitive sensory nerves. Cardiovasc Haematol Disorders Drug Targets. (2007) 7: 37– 46. 10.2174/187152907780059100 17346127 · DOI
  87. [91]Yu S-q Wang DH. Enhanced salt sensitivity following shRNA silencing of neuronal TRPV1 in rat spinal cord. Acta Pharmacol Sinica. (2011) 32: 845– 52. 10.1038/aps.2011.43 21642952 PMC4009958 · DOI
  88. [92]Martyniuk CJ Martinez R Kostyniuk DJ Mennigen JA Zubcevic JJPG. Genetic ablation of bone marrow beta-adrenergic receptors in mice modulates miRNA-transcriptome networks of neuroinflammation in the paraventricular nucleus. Physiol Genomics. (2020) 52: 169– 77. 10.1152/physiolgenomics.00001.2020 32089076 PMC7191424 · DOI
  89. [93]Ahmari N Schmidt JT Krane GA Malphurs W Cunningham BE Owen JL. Loss of bone marrow adrenergic beta 1 and 2 receptors modifies transcriptional networks, reduces circulating inflammatory factors, and regulates blood pressure. Physiol Genomics. (2016) 48: 526– 36. 10.1152/physiolgenomics.00039.2016 27235450 PMC11735009 · DOI
  90. [94]Yang G Istas G Höges S Yakoub M Hendgen-Cotta U Rassaf T. Angiotensin-(1-7)-induced Mas receptor activation attenuates atherosclerosis through a nitric oxide-dependent mechanism in apolipoprotein E-KO mice. Pflügers Arch. (2018) 470: 661– 7. 10.1007/s00424-018-2108-1 29352340 · DOI

Cited by

Sorted by citations

Authors
Ciftciler, R., & Haznedaroglu, I. C.
Venue
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Published
2020-08-07
Volume
11
Pages
425-425
ISSN
1664-2392 (ISSN-L)
DOI
10.3389/fendo.2020.00425
PMC
PMC7438890
OpenAlex
W3047881279
Cited by
20
References
3
Citations by year
2026: 2 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 3 · 2020: 1
FWCI
0.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal and Vascular Pathologies
Keywords
local renin-angiotensin system, bone marrow, systemic arterial hypertension, central nervous system, angiotensin-(1-7), Mas receptor, angiotensinogen, hematopoietic stem cells, atherosclerosis, macrophages, myeloid cells, re-endothelialization, inflammation, renin-angiotensin system inhibitors
MeSH terms
Animals, Bone Marrow, Cardiovascular Physiological Phenomena, Central Nervous System, Humans, Hypertension, Renin-Angiotensin System

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review